Marijke Vroomen Durning, RN

Agents that inhibit SHP2 attack cancer cells in a way that is distinct from other therapies, and data showing the potential efficacy of such therapies, are fueling more research.

The pandemic brought about by severe acute respiratory syndrome coronavirus 2 has put some aspects of life on hold for over a year now. However, for people living with serious and potentially fatal illnesses, putting life on hold is not an option.

A tumor-agnostic approach in which treatment is developed based on a tumor’s genetic and molecular features without regard to the cancer type or primary tumor location in the body, is the focus of the National Cancer Institute -MATCH trial.

Relevant professional meetings and oncology publications exploded with research and news about chimeric antigen receptor T cells, and this cellular therapy strategy is now being explored across hematologic and solid malignancies.

When checkpoint inhibitors<strong>&nbsp;</strong>were introduced, it had been more than 30 years since any new drugs had been approved for the treatment of urothelial cancer. Recently, 2 new non&ndash;checkpoint inhibitors, erdafitinib and enfortumab vedotin-ejfv, reached the market, and more may be available soon.

As cancer therapies have evolved and individualized treatments have de-veloped over time, patient-centered care has become more prevalent, and oncology teams must consider it to maximize the chances of positive patient outcomes.

Immunotherapy is fast becoming the new standard of care for non-small-cell lung cancer alongside developing research in the field.

Young black women have a higher prevalence of BRCA mutations compared with that previously reported among non-Hispanic white women.

The biomarker E2F4 predicts survival in breast cancer, and an article recently published in the journal Molecular Cancer Research indicates that E2F4 may also predict progression and immunotherapy efficacy in bladder cancer.